Decoy Therapeutics Registers 3.77M Shares for Resale
Decoy Therapeutics Inc. filed an S-1 registration statement for the resale of up to 3,766,500 shares of common stock by selling stockholders. These shares are issuable upon the exercise of Pre-Funded, Milestone, and Placement Agent Warrants, which were issued in a private placement that closed on June 29, 2026, generating $3.5 million in upfront gross proceeds for the company. While the company will not receive proceeds from the resale, it could receive approximately $19.1 million if all warrants are exercised for cash, intended for working capital and general corporate purposes. Decoy Therapeutics is a pre-clinical stage biotechnology company facing substantial doubt about its ability to continue as a going concern, with existing cash expected to fund operations only into late 2026.
Key Highlights
- Registration of up to 3,766,500 common shares for resale by selling stockholders.
- Shares are issuable upon exercise of Pre-Funded, Milestone, and Placement Agent Warrants.
- Private placement closed June 29, 2026, generating $3.5 million in upfront gross proceeds.
- Potential additional $19.1 million from cash exercise of all warrants for working capital.
- Company faces substantial doubt about going concern, cash sufficient only into late 2026.
- Milestone Warrants require stockholder approval and milestone events to become exercisable.
- Common stock outstanding as of June 9, 2026, was 531,968 shares.
- Decoy Therapeutics is a smaller reporting company and non-accelerated filer.
Price Impact
More from DCOY
More in Corporate Action